Association Between NOS3 Gene G894T Polymorphism and Late-onset Alzheimer Disease in a Sample From Iran

Alzheimer disease (AD) is the most common age-associated neurodegenerative disease caused by complicated interactions between genetic and environmental factors. The presence of the apolipoprotein ϵ4 allele, the only confirmed genetic risk factor for late-onset AD (LOAD), is neither sufficient nor necessary to explain all occurrences of the disease. Aberrant expression of the endothelial nitric oxide synthase (NOS3) gene has been demonstrated in degenerating neurons and glial cells in brains with AD. Molecular epidemiologic studies have presented contradictory results concerning a potential role of NOS3 gene G894T polymorphism in AD. To define a possible association of this polymorphism with LOAD in an Iranian population, we conducted a case-control study including a clinically well-defined group of 100 LOAD patients and 100 age-matched controls. G894T polymorphism in NOS3 gene was determined by polymerase chain reaction-restriction fragment length polymorphisms assay. Chi-square analysis showed a significantly increased number of individuals with the G/G genotype in AD patients compared with controls (P<0.05). These results demonstrate an association between G894T polymorphism and LOAD in an Iranian sample and the G/G genotype seems to have some effects in the development of AD either alone or through interaction with other risk factors.

[1]  A. Pfeffer,et al.  Simultaneous analysis of five genetic risk factors in Polish patients with Alzheimer's disease , 2003, Neuroscience Letters.

[2]  H. McNulty,et al.  Genetic Evidence That Nitric Oxide Modulates Homocysteine: The NOS3 894TT Genotype Is a Risk Factor for Hyperhomocystenemia , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[3]  J. Tanus-Santos,et al.  Effects of ethnicity on the distribution of clinically relevant endothelial nitric oxide variants. , 2001, Pharmacogenetics.

[4]  T. Arendt,et al.  Aberrant expression of NOS isoforms in Alzheimer’s disease is structurally related to nitrotyrosine formation , 2002, Brain Research.

[5]  C. Plata-salamán,et al.  Inflammation and Alzheimer’s disease , 2000, Neurobiology of Aging.

[6]  J. Moss,et al.  Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[7]  S H Snyder,et al.  Endothelial nitric oxide synthase localized to hippocampal pyramidal cells: implications for synaptic plasticity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Binbin Wang,et al.  Association Between Alzheimer’s Disease and the NOS3 gene Glu298Asp Polymorphism in Chinese , 2008, Journal of Molecular Neuroscience.

[9]  Xiongwei Zhu,et al.  Vascular oxidative stress in Alzheimer disease , 2007, Journal of the Neurological Sciences.

[10]  D. Panagiotakos,et al.  Evidence for association between endothelial nitric oxide synthase gene polymorphism (G894T) and inflammatory markers: the ATTICA study. , 2004, American heart journal.

[11]  Yadong Huang.  Apolipoprotein E and Alzheimer disease , 2006, Neurology.

[12]  B. Mayer,et al.  Functional characterization of Glu298Asp mutant human endothelial nitric oxide synthase purified from a yeast expression system. , 2003, Nitric oxide : biology and chemistry.

[13]  Amit A. Doshi,et al.  Endothelial nitric oxide synthase gene: prospects for treatment of heart disease. , 2007, Pharmacogenomics.

[14]  C. Shin,et al.  Lack of evidence for contribution of Glu298Asp (G894T) polymorphism of endothelial nitric oxide synthase gene to plasma nitric oxide levels. , 2002, Thrombosis research.

[15]  C. Caruso,et al.  Alzheimer's disease and genetics of inflammation: a pharmacogenomic vision. , 2007, Pharmacogenomics.

[16]  C. Barbagallo,et al.  No association between Glu298Asp endothelial nitric oxide synthase polymorphism and Italian sporadic Alzheimer's disease , 2003, Neuroscience Letters.

[17]  N. Kato,et al.  No evidence for an association between the Glu298Asp polymorphism of the NOS3 gene and Alzheimer's disease , 2000, Journal of Neural Transmission.

[18]  T. Mahjoub,et al.  ORIGINAL ARTICLE: Lack of Consistent Association Between Endothelial Nitric Oxide Synthase Gene Polymorphisms, Homocysteine Levels and Recurrent Pregnancy Loss in Tunisian Women , 2008, American journal of reproductive immunology.

[19]  N. Alp,et al.  Functional comparison of the endothelial nitric oxide synthase Glu298Asp polymorphic variants in human endothelial cells. , 2004, Pharmacogenetics.

[20]  J. Chiche,et al.  Nitric Oxide Synthase-3 Overexpression Causes Apoptosis and Impairs Neuronal Mitochondrial Function: Relevance to Alzheimer's-Type Neurodegeneration , 2003, Laboratory Investigation.

[21]  G. Gibson,et al.  Oxidative Stress and Transcriptional Regulation in Alzheimer Disease , 2007, Alzheimer disease and associated disorders.

[22]  T. Malinski.  Nitric oxide and nitroxidative stress in Alzheimer's disease. , 2007, Journal of Alzheimer's disease : JAD.

[23]  O. Combarros,et al.  The Glu298Asp polymorphism in the NOS3 gene is not associated with sporadic Alzheimer's disease , 2001, Journal of neurology, neurosurgery, and psychiatry.

[24]  L. Cupples,et al.  Genetic association between endothelial nitric oxide synthase and Alzheimer disease , 2006, Clinical genetics.

[25]  Roger N Rosenberg,et al.  Genome-wide association studies in Alzheimer disease. , 2008, Archives of neurology.

[26]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[27]  Z. Janka,et al.  The nitric oxide synthase-3 codon 298 polymorphism is not associated with late-onset sporadic Alzheimer's dementia and Lewy body disease in a sample from Hungary , 2003, Psychiatric genetics.

[28]  C. Ntais,et al.  Association of the endothelial nitric oxide synthase (NOS3) Glu298Asp gene polymorphism with the risk of Alzheimer's disease , 2005, Journal of Neurology.

[29]  S. Scherer,et al.  Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. , 1993, The Journal of biological chemistry.

[30]  J. Wands,et al.  Aberrant expression of nitric oxide synthase III in Alzheimer’s disease: relevance to cerebral vasculopathy and neurodegeneration , 2000, Neurobiology of Aging.

[31]  Ramón Cacabelos,et al.  Pharmacogenomics in Alzheimer's disease. , 2000, Methods in molecular biology.

[32]  A. Burns.  Clinical diagnosis of Alzheimer's disease , 1991 .

[33]  M. Selley.  Increased concentrations of homocysteine and asymmetric dimethylarginine and decreased concentrations of nitric oxide in the plasma of patients with Alzheimer’s disease , 2003, Neurobiology of Aging.

[34]  J. Wang,et al.  Endothelial nitric oxide synthase gene sequence variations and vascular disease. , 2000, Molecular genetics and metabolism.

[35]  Zhenxin Zhang,et al.  [Association between Alzheimer's disease and nitric oxide synthase III polymorphism]. , 2004, Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae.

[36]  G. Breen,et al.  Association between Alzheimer's disease and the NOS3 gene , 1999, Annals of neurology.

[37]  A. Singleton,et al.  Nitric oxide synthase gene polymorphisms in Alzheimer's disease and dementia with Lewy bodies , 2001, Neuroscience Letters.

[38]  J. Morrow,et al.  In-vivo effects of Glu298Asp endothelial nitric oxide synthase polymorphism. , 2001, Pharmacogenetics.

[39]  L. Feuk,et al.  Lack of replication of association findings in complex disease: an analysis of 15 polymorphisms in prior candidate genes for sporadic Alzheimer's disease , 2001, European Journal of Human Genetics.

[40]  N. Bresolin,et al.  Influence of the Glu298Asp polymorphism of NOS3 on age at onset and homocysteine levels in AD patients , 2005, Neurobiology of Aging.